Click here to open the filter panel
R
Randomised clinical trial (RCT)
R
Real-world data (RWD)
R
Real-world evidence (RWE)
R
Recipient
R
Record of processing activities (RoPA)
R
Regulatory intelligence
R
Re-identification risk (motivated intruder test)
R
Restriction of processing
R
Right not to be subject to solely automated decision-making
R
Right of access
R
Right of information
R
Right of rectification
R
Rights of the data subject
R
Right to data portability
R
Right to erasure ("right to be forgotten")
R
Right to object
R
Right to restriction of processing
S
Schrems II
S
Scientific research purposes (Art. 89 GDPR)
S
Secondary use of health data
S
Security breach (security incident)
S
Security of processing
S
Sensitive data
S
Serious adverse event (SAE)
S
Shadow AI
S
Site management organisation (SMO)
S
SNDS (Système National des Données de Santé)
S
Software as a Medical Device (SaMD)
S
Source data verification (SDV) and source documents
S
Special categories of personal data
S
Sponsor
S
Standard contractual clauses (SCC)
S
Start of a clinical trial
S
Storage limitation (limited storage periods)
S
Study Data Tabulation Model (SDTM)
S
Subject (clinical trial participant)
S
Sub-processor
S
Supervisory authority
S
Supplementary measures
S
Swiss Federal Act on Data Protection (FADP / revFADP)
S
Swissmedic
S
Synthetic data
T
Technical and organisational measures (TOMs)
T
Temporary halt of a clinical trial
T
Third country
T
Third party
T
Transfer impact assessment (TIA)
T
Trial master file (TMF)
T
Trusted research environment (TRE)
U
UK GDPR
U
Unexpected serious adverse reaction (SUSAR)
U
US CLOUD Act
V
Validation (computerised system validation, CSV)
V
Vendor assessment (third-party risk management)
V
Vital interests (Art. 6(1)(d) GDPR)
V
Vulnerable participants (vulnerable subjects)
W
Wearables and digital health technologies (DHT)
W
Withdrawal (of consent and from a clinical trial)
W
World Health Organization (WHO)
X
XAI (explainable artificial intelligence)
Y
Yellow Card scheme (UK)
Z
Zero-knowledge proof
Z
Zero trust architecture
Click a letter to view all its definitions
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.

Term of the Day

Natural history study

A natural history study is a preplanned observational study intended to track the course of a disease over time, identifying demographic, genetic, environmental and other variables that correlate with its development and outcomes in the absence of intervention, or under standard of care. Designs may be retrospective (chart review of existing records) or prospective (longitudinal follow-up of a cohort or registry).

Natural history data is particularly important in rare and paediatric diseases, where randomised placebo-controlled trials may be infeasible or unethical. The FDA (guidance on rare disease natural history studies, 2019) and the EMA accept well-designed natural history studies to define endpoints and biomarkers, identify patient subgroups, estimate sample sizes and, in some cases, serve as external or historical control arms for single-arm trials supporting orphan products.

Because they are non-interventional, natural history studies fall outside the CTR and are governed by national law (for example France's MR-003 or MR-004 reference methodologies) and by the GDPR. They typically involve secondary use of medical records, long-term follow-up, genetic data and small populations in which anonymisation is rarely achievable, so pseudonymisation, a DPIA and a robust research legal basis under Art. 9(2)(j) are essential. Registries maintained by patient organisations or academic consortia raise additional questions of joint controllership and data access governance.

I

ICH E6(R3)

ICH E6(R3) is the third revision of the International Council for Harmonisation guideline on Good Clinical Practice. It describes principles and practices for ethically and scientifically sound clinical trials, with emphasis on proportionate quality management and reliable results. Implementation depends on the jurisdiction and the particular part of the guideline.

Key takeaways

  • Focus controls on what matters to the trial.
  • Treat data governance as a lifecycle activity.
  • Check the applicable annex and local implementation.

Implementation and Operational Focus

The EMA guideline page distinguishes the EU implementation dates below. The FDA issued final E6(R3) guidance in September 2025; guidance status should not be confused with a universal statutory commencement date.

ElementPosition on 27 October 2026
EU Principles and Annex 1Effective from 23 July 2025.
EU Annex 2Effective from 15 January 2027.
Operational directionQuality by design, proportionate controls and fit-for-purpose systems.

Why It Matters for Data Protection

Compared with treating compliance as a uniform checklist, the practical emphasis is on identifying critical factors and matching controls to the study. Our recommendation is to bring clinical operations, quality and privacy teams into that assessment together. Document why each data element is needed, how responsibilities are allocated and how access, corrections and retention will be handled. GCP assessment does not replace a separate privacy-law assessment.

Hypothetical example: A sponsor introducing remote follow-up identifies identity checks and endpoint completeness as important risks. It tests those workflows, clarifies supplier responsibilities and limits access to identifiable records. The team documents its reasoning and applicable guidance version rather than assuming that adding more monitoring activities always improves quality.

Frequently Asked Questions

Is every part already effective in the EU?

No. The EMA lists a later effective date for Annex 2 than for Principles and Annex 1.

Does R3 remove the need for oversight?

No. Proportionate management means justified controls, not an absence of oversight.

Is ICH E6(R3) the same as GDPR?

No. Assess trial quality requirements and applicable data protection obligations separately.

Related reading: Good Clinical Practice, GCP and GDPR. For practical support, see clinical operations and regulatory affairs support.

Updated: 27 October 2026